Diagnostic accuracy of prostate cancer antigen 3 (PCA3) prior to first prostate biopsy: A systematic review and meta-analysis.

Diagnostic accuracy of prostate cancer antigen 3 (PCA3) prior to first prostate biopsy: A systematic review and meta-analysis.: We aimed to determine the diagnostic accuracy of the prostate cancer antigen 3 (PCA3) test before performing the first biopsy compared with prostate biopsy for the diagnosis of prostate cancer.A systematic search was performed in MEDLINE, EMBASE, CENTRAL, LILACS, reference lists, specialized journals in urology and cancer, and unpublished literature.






urotoday.com

Diagnostic accuracy of prostate cancer antigen 3 (PCA3) prior to first prostate biopsy: A systematic review and meta-analysis.

2 minutes














We aimed to determine the diagnostic accuracy of the prostate cancer
antigen 3 (PCA3) test before performing the first biopsy compared with
prostate biopsy for the diagnosis of prostate cancer.

A systematic
search was performed in MEDLINE, EMBASE, CENTRAL, LILACS, reference
lists, specialized journals in urology and cancer, and unpublished
literature. The population was adults with suspected prostate cancer,
and the intervention was the measurement of PCA3 in urine samples for
the diagnosis of prostate cancer. The quality of studies was evaluated
with the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2)
tool. The operative characteristics were determined, and a meta-analysis
was performed.



Nine studies of diagnostic tests were included
based on a cutoff value of 35. The following overall values were
obtained:

  • the sensitivity was 0.69 (95% confidence interval [CI]
    0.61-0.75); 
  • specificity was 0.65 (95% CI 0.553-0.733); 
  • the diagnostic
    odds ratio (DOR) was 4.244 (95% CI 3.487-5.166); and 
  • the area under the
    curve was 0.734 (95% CI 0.674-0.805) with a heterogeneity of 0%.


Urinary
PCA3 has an acceptable diagnostic accuracy, aids in the study of
patients with suspected prostate cancer, and can be used as a guide for
directing the performance of the first prostate biopsy and decreasing
unnecessary biopsies.



Canadian Urological Association journal = Journal de l'Association des urologues du Canada. 2019 Nov 29 [Epub ahead of print]

Sandra Viviana Muñoz Rodríguez

Herney Andrés García-Perdomo Universidad Libre de Colombia, Bogotá, Columbia; Universidad del Valle, Valle del Cauca, Columbia.

PubMed http://www.ncbi.nlm.nih.gov/pubmed/31793864







Comments

Post a Comment

Popular posts from this blog

A 10-Second Steam Blast: The New Weapon Against Prostate Cancer?

Image
Vanquish® Water Vapor Ablation System, Francis Medical Steams Out Prostate Cancer The Vanquish® Water Vapor Ablation System, developed by Francis Medical, Inc. , represents an innovative approach to treating prostate cancer using water vapor (steam) to ablate cancerous tissue. This minimally invasive technique aims to target and destroy prostate cancer cells while minimizing damage to surrounding healthy tissue, potentially reducing common side effects associated with traditional treatments like surgery and radiation, Mechanism of Action:  The Vanquish system utilizes the thermal energy stored in sterile water vapor to ablate cancerous prostate tissue. During the procedure, a catheter is inserted through the urethra into the prostate, delivering water vapor directly to the targeted tissue. As the vapor condenses back into liquid, it releases stored thermal energy, effectively destroying the cancerous cells. This method is designed to respect the prostate's natural boundaries, ...
Read more

Researchers develop low-cost device that detects cancer in an hour | ScienceDaily

Image
Summary Sanjay S. Timilsina , currently Lead Scientist, StataDx, a spinoff from Wyss Institute, former Postdoctoral Fellow at Harvard Medical School and the Wyss Institute at Harvard University, PhD from UTEP Department of Chemistry & Biochemistry, and XiuJun Li full Professor in the Department of Chemistry and Biochemistry and of Forensic Science, & Environmental Science and Engineering, at the University of Texas at El Paso (UTEP) have developed a new portable device for cancer detection that offers several advantages over traditional methods: Key Features: - Low cost (a few dollars per device, <8 cents per assay) - Provides results in about 1 hour (vs. 12-16 hours for traditional methods) - Approximately 10 times more sensitive than traditional methods - Portable and doesn't require specialized instruments - Can detect both CEA colorectal and PSA prostate cancer biomarkers - Uses a "paper-in-polymer-pond" structure to analyze blood samples How it works: - U...
Read more

Cancer patients and doctors team up to change how cancer drugs are tested | Fox News

Cancer patients and doctors team up to change how cancer drugs are tested | Fox News foxnews.com Associated Press For cancer patients, the harsh side effects of powerful drugs have long been the trade-off for living longer. Now, patients and doctors are questioning whether all that suffering is necessary. They’ve ignited a movement to radically change how new cancer drugs are tested, with the U.S. Food and Drug Administration urging drugmakers to do a better job at finding the lowest effective dose, even if it takes more time. Advances in treatment mean millions of people are surviving for years with incurable cancers. Jill Feldman, 54, of Deerfield, Illinois, has lived 15 years with lung cancer , thanks to that progress. Her parents both died of lung cancer months after their diagnoses. But her cancer drug causes joint pain, fatigue and mouth sores that m...
Read more